[Anti DIC therapy]

Area of Science:

• Hematology
• Critical Care Medicine
• Pharmacology

Background:

• Disseminated intravascular coagulation (DIC) is a complex syndrome characterized by dysregulated activation of coagulation and fibrinolysis.
• Unbalanced activation of these systems leads to widespread microthrombi formation and consumption of clotting factors and platelets.
• DIC can arise from various conditions, including sepsis and trauma, necessitating tailored therapeutic approaches.

Purpose of the Study:

• To review the therapeutic strategies for disseminated intravascular coagulation (DIC).
• To highlight the importance of selecting appropriate anti-DIC agents based on their pharmacological properties.
• To discuss the differential indications for anticoagulation and antifibrinolytic therapy in DIC.

Main Methods:

• Literature review of current therapeutic options for DIC.
• Analysis of the role of anticoagulation and antifibrinolytic therapies in different DIC etiologies.
• Consideration of pharmacological properties of available anti-DIC agents.

Main Results:

• Auxiliary treatments can improve outcomes in DIC when used alongside primary disease management.
• Anticoagulation is indicated in sepsis-induced DIC where coagulation activation predominates.
• In trauma-associated DIC, where coagulation and fibrinolysis balance is rapidly disrupted, both anticoagulation and antifibrinolytic therapies may be employed based on clinical status.

Conclusions:

• The choice of anti-DIC agents requires careful consideration of their pharmacological profiles.
• Tailoring treatment strategies, including anticoagulation and antifibrinolysis, to the specific cause of DIC is crucial for effective management.
• Understanding the distinct pathophysiological mechanisms in sepsis- and trauma-induced DIC guides therapeutic decision-making.